Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19

Background: The cause of coronavirus disease 2019 (COVID-19) is a virus which can lead to severe acute respiratory syndrome-CoV-2 (SARS-COV-2). There are evidences of involvement of immune system in pathogenesis of this disease. We investigated the presence of various vasculitis-associated autoantib...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maryam Mobini, Roya Ghasemian, Laleh Vahedi Larijani, Maede Mataji, Iradj Maleki
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer Medknow Publications 2021
Materias:	antinuclear antibody complement activation covid-19 rheumatoid factor vasculitis Medicine R
Acceso en línea:	https://doaj.org/article/7b59ab72ad8e48e8a03c95cfe7739bf7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b59ab72ad8e48e8a03c95cfe7739bf7
record_format	dspace
spelling	oai:doaj.org-article:7b59ab72ad8e48e8a03c95cfe7739bf72021-11-12T10:25:24ZImmunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-191735-19951735-713610.4103/jrms.JRMS_923_20https://doaj.org/article/7b59ab72ad8e48e8a03c95cfe7739bf72021-01-01T00:00:00Zhttp://www.jmsjournal.net/article.asp?issn=1735-1995;year=2021;volume=26;issue=1;spage=103;epage=103;aulast=Mobinihttps://doaj.org/toc/1735-1995https://doaj.org/toc/1735-7136Background: The cause of coronavirus disease 2019 (COVID-19) is a virus which can lead to severe acute respiratory syndrome-CoV-2 (SARS-COV-2). There are evidences of involvement of immune system in pathogenesis of this disease. We investigated the presence of various vasculitis-associated autoantibodies and complement levels in patients with COVID-19. Materials and Methods: Patients with severe or critical type of COVID-19 were evaluated for symptoms, signs, and laboratory tests of vasculitis syndromes including rheumatoid factor (RF), antinuclear antibody (ANA), anti-double-stranded DNA, c and p anti-neutrophilic cytoplasmic antibody (c ANCA and P ANCA), and complement levels. Results: The study was performed in forty patients with severe or critical illness. The mean age of the participants was 48.5 ± 9.8 years. All patients had pulmonary involvement in lung computed tomography scans. Vasculitis laboratory test results included RF in two patients, ANA in three patients, and ANCA in one patient. Seventeen (42.5%) patients had hypocomplementemia in one or more complement tests. Four patients expired, of whom three had a decrease in complement level. Conclusion: Decrease in complement levels may predict a critical state of COVID-19 disease. Therefore, measuring its levels may be of great benefit in making earlier decisions to initiate disease-suppressing treatments including corticosteroids.Maryam MobiniRoya GhasemianLaleh Vahedi LarijaniMaede MatajiIradj MalekiWolters Kluwer Medknow Publicationsarticleantinuclear antibodycomplement activationcovid-19rheumatoid factorvasculitisMedicineRENJournal of Research in Medical Sciences, Vol 26, Iss 1, Pp 103-103 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antinuclear antibody complement activation covid-19 rheumatoid factor vasculitis Medicine R
spellingShingle	antinuclear antibody complement activation covid-19 rheumatoid factor vasculitis Medicine R Maryam Mobini Roya Ghasemian Laleh Vahedi Larijani Maede Mataji Iradj Maleki Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19
description	Background: The cause of coronavirus disease 2019 (COVID-19) is a virus which can lead to severe acute respiratory syndrome-CoV-2 (SARS-COV-2). There are evidences of involvement of immune system in pathogenesis of this disease. We investigated the presence of various vasculitis-associated autoantibodies and complement levels in patients with COVID-19. Materials and Methods: Patients with severe or critical type of COVID-19 were evaluated for symptoms, signs, and laboratory tests of vasculitis syndromes including rheumatoid factor (RF), antinuclear antibody (ANA), anti-double-stranded DNA, c and p anti-neutrophilic cytoplasmic antibody (c ANCA and P ANCA), and complement levels. Results: The study was performed in forty patients with severe or critical illness. The mean age of the participants was 48.5 ± 9.8 years. All patients had pulmonary involvement in lung computed tomography scans. Vasculitis laboratory test results included RF in two patients, ANA in three patients, and ANCA in one patient. Seventeen (42.5%) patients had hypocomplementemia in one or more complement tests. Four patients expired, of whom three had a decrease in complement level. Conclusion: Decrease in complement levels may predict a critical state of COVID-19 disease. Therefore, measuring its levels may be of great benefit in making earlier decisions to initiate disease-suppressing treatments including corticosteroids.
format	article
author	Maryam Mobini Roya Ghasemian Laleh Vahedi Larijani Maede Mataji Iradj Maleki
author_facet	Maryam Mobini Roya Ghasemian Laleh Vahedi Larijani Maede Mataji Iradj Maleki
author_sort	Maryam Mobini
title	Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19
title_short	Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19
title_full	Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19
title_fullStr	Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19
title_full_unstemmed	Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19
title_sort	immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with covid-19
publisher	Wolters Kluwer Medknow Publications
publishDate	2021
url	https://doaj.org/article/7b59ab72ad8e48e8a03c95cfe7739bf7
work_keys_str_mv	AT maryammobini immunologicmarkersvasculitisassociatedautoantibodiesandcomplementlevelsinpatientswithcovid19 AT royaghasemian immunologicmarkersvasculitisassociatedautoantibodiesandcomplementlevelsinpatientswithcovid19 AT lalehvahedilarijani immunologicmarkersvasculitisassociatedautoantibodiesandcomplementlevelsinpatientswithcovid19 AT maedemataji immunologicmarkersvasculitisassociatedautoantibodiesandcomplementlevelsinpatientswithcovid19 AT iradjmaleki immunologicmarkersvasculitisassociatedautoantibodiesandcomplementlevelsinpatientswithcovid19
_version_	1718430997621506048

Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19

Ejemplares similares